Ervebo Vaccine Provides Cross-Protection Against Bundibugyo Virus Infection in Macaques

The 2026 Bundibugyo virus (BDBV) disease outbreak in the Democratic Republic of the Congo (DRC) was declared a public health emergency (PHEIC) in May 2026 (1). Regional security concerns, debilitated medical infrastructure, diagnostic limitations, and lack of approved BDBV–specific medical countermeasures have contributed to rapid escalation of the outbreak (2). Currently, there are no licensed medical countermeasures for BDBV (3). Several BDBV-specific vaccines are in development (4), including a vesicular stomatitis virus (VSV)–based vaccine expressing the BDBV glycoprotein which has demonstrated strong preclinical efficacy (5-7); however, these candidates have not yet completed clinical evaluation. A licensed VSV-based vaccine expressing the Ebola virus glycoprotein (VSV-EBOV) (8) is available for human use and clinical (ERVEBO) and research grade (VSV-EBOV) material has been shown to elicit cross-reactive, cross-neutralizing and inconclusive cross-protective immune responses against the related BDBV (5,9-14). ERVEBO’s protective efficacy against BDBV, however, has not been formally established in the standard macaque model of BDBV infection. Macaques received a single human dose of ERVEBO or an unrelated VSV-based control vaccine and were challenged with BDBV 14 days after vaccination. ERVEBO vaccinated macaques exhibited significantly reduced clinical disease and strikingly increased survival, as well as significantly reduced viremia, mucosal viral shedding and disease-associated biochemistry markers consistent with protection against BDBV-mediated hepatorenal disease. These findings indicate that ERVEBO can rapidly mediate cross-protective immunity against BDBV.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11694971/v1
Primary Topic
Viral Infections and Outbreaks Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Ervebo Vaccine Provides Cross-Protection Against Bundibugyo Virus Infection in Macaques

Kyle Lee O’Donnell, Ekaterina S Altynova, Kyle Rosenke, Thomas Tipih et al.
Research Square
Viral Infections and Outbreaks Research
preprint

Ervebo Vaccine Provides Cross-Protection Against Bundibugyo Virus Infection in Macaques

Kyle Lee O’Donnell, Ekaterina S Altynova, Kyle Rosenke, Thomas Tipih, Hannah van Riel, Shanna Brown, Chad S. Clancy, Heinz Feldmann, Atsuhi Okumura, Andrea Marzi, Paige Fletcher, ANANDHI KANNAN, Trenton Bushmaker, Aaron Carmody, Axel T. Lehrer, Akash Rajeev, Amanda Griffin, Samantha Ertl, Vignesh Mariappan, Brian Smith
preprint en

Abstract

The 2026 Bundibugyo virus (BDBV) disease outbreak in the Democratic Republic of the Congo (DRC) was declared a public health emergency (PHEIC) in May 2026 (1). Regional security concerns, debilitated medical infrastructure, diagnostic limitations, and lack of approved BDBV–specific medical countermeasures have contributed to rapid escalation of the outbreak (2). Currently, there are no licensed medical countermeasures for BDBV (3). Several BDBV-specific vaccines are in development (4), including a vesicular stomatitis virus (VSV)–based vaccine expressing the BDBV glycoprotein which has demonstrated strong preclinical efficacy (5-7); however, these candidates have not yet completed clinical evaluation. A licensed VSV-based vaccine expressing the Ebola virus glycoprotein (VSV-EBOV) (8) is available for human use and clinical (ERVEBO) and research grade (VSV-EBOV) material has been shown to elicit cross-reactive, cross-neutralizing and inconclusive cross-protective immune responses against the related BDBV (5,9-14). ERVEBO’s protective efficacy against BDBV, however, has not been formally established in the standard macaque model of BDBV infection. Macaques received a single human dose of ERVEBO or an unrelated VSV-based control vaccine and were challenged with BDBV 14 days after vaccination. ERVEBO vaccinated macaques exhibited significantly reduced clinical disease and strikingly increased survival, as well as significantly reduced viremia, mucosal viral shedding and disease-associated biochemistry markers consistent with protection against BDBV-mediated hepatorenal disease. These findings indicate that ERVEBO can rapidly mediate cross-protective immunity against BDBV.

Research Square
University of Hawaiʻi at Mānoa (US), National Institutes of Health (US), National Institute of Allergy and Infectious Diseases (US), Rocky Mountain Laboratories (US)
Viral Infections and Outbreaks Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon